^
Association details:
| Biomarker: | PIK3CA amplification |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | taselisib (GDC-0032) (PIK3CA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Taselisib (GDC-0032), a Potent ß-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations
Excerpt:
Cell lines harboring either mutations or amplification of PIK3CA tended to be sensitive to GDC-0032, with IC50 values in the nanomolar range (Fig. 1A).
DOI:
10.1158/1078-0432.CCR-15-2245
